Lipocine to Present at 2016 Ladenburg Thalmann Healthcare Conference
September 20, 2016 08:00 ET
|
Lipocine, Inc.
SALT LAKE CITY, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
Lipocine Announces Financial and Operational Results for the Second Quarter of 2016
August 09, 2016 08:00 ET
|
Lipocine, Inc.
SALT LAKE CITY, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the quarter ended June 30,...
Lipocine to Present at 36th Annual Canaccord Genuity Growth Conference
August 04, 2016 08:00 ET
|
Lipocine, Inc.
SALT LAKE CITY, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive...
Lipocine Receives Complete Response Letter (CRL) for LPCN 1021 From U.S. Food and Drug Administration
June 29, 2016 06:55 ET
|
Lipocine, Inc.
SALT LAKE CITY, June 29, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has received a Complete Response Letter (“CRL”) from...
Lipocine Added to Russell 3000 and Russell Global Indexes
June 27, 2016 08:00 ET
|
Lipocine, Inc.
SALT LAKE CITY, June 27, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has been added to the Russell 3000® and Russell Global®...
Lipocine Announces Financial and Operational Results for the First Quarter of 2016
May 09, 2016 16:00 ET
|
Lipocine Inc.
SALT LAKE CITY, May 09, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the quarter ended March 31,...
Lipocine Announces the Presentation of Clinical Data for Oral Testosterone Replacement Therapy Product Candidate TLANDO™ (“LPCN 1021”) at the 2016 American Urological Association Annual Meeting
May 02, 2016 08:00 ET
|
Lipocine Inc.
SALT LAKE CITY, May 02, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for lead candidate TLANDO™ (“LPCN 1021”),...
Lipocine to Present at 15th Annual Needham & Company Healthcare Conference
April 06, 2016 13:58 ET
|
Lipocine Inc.
SALT LAKE CITY, April 06, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
Lipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at the American Society of Andrology 41st Annual Conference
March 28, 2016 08:30 ET
|
Lipocine Inc.
SALT LAKE CITY, March 28, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone...
Lipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at ENDO 2016
March 28, 2016 08:30 ET
|
Lipocine Inc.
SALT LAKE CITY, March 28, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone...